Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly understood. Here we study two prototypical...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhireksan, Zenita, Davey, Gabriela E., Campomanes, Pablo, Groessl, Michael, Clavel, Catherine M., Yu, Haojie, Nazarov, Alexey A., Yeo, Charmian Hui Fang, Ang, Wee Han, Dröge, Peter, Rothlisberger, Ursula, Dyson, Paul J., Davey, Curt A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959212/
https://www.ncbi.nlm.nih.gov/pubmed/24637564
http://dx.doi.org/10.1038/ncomms4462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959212/
https://www.ncbi.nlm.nih.gov/pubmed/24637564
http://dx.doi.org/10.1038/ncomms4462

Ejemplares similares